Company Description
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery.
It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| Country | United States |
| Founded | 1886 |
| IPO Date | Sep 24, 1944 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 131,900 |
| CEO | Joaquin Duato |
Contact Details
Address: One Johnson & Johnson Plz New Brunswick, New Jersey 08933 United States | |
| Phone | 732-524-2455 |
| Website | jnj.com |
Stock Details
| Ticker Symbol | JNJ |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000200406 |
| CUSIP Number | 478160104 |
| ISIN Number | US4781601046 |
| Employer ID | 22-1024240 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joaquin Duato | Chief Executive Officer and Chairman |
| Joseph J. Wolk CPA | Executive Vice President and Chief Financial Officer |
| Dr. Peter M. Fasolo Ph.D. | Executive Vice President and Chief Human Resources Officer |
| Jennifer L. Taubert | Executive Vice President and Worldwide Chairman of Innovative Medicine |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, Research & Development |
| Robert J. Decker Jr. | Controller and Chief Accounting Officer |
| James Swanson | Executive Vice President and Chief Information Officer |
| Jessica Moore | Vice President of Investor Relations |
| Dirk Brinckman | Chief Compliance Officer |
| Elizabeth Forminard | Executive Vice President and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K/A | [Amend] Current report |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 10, 2024 | 3 | Initial statement of beneficial ownership of securities |
| Mar 27, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 13, 2024 | 144 | Filing |
| Mar 13, 2024 | ARS | Filing |
| Mar 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2024 | 4 | Statement of changes in beneficial ownership of securities |